Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Affimed N.V.

< Previous 1 2 Next >
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Present at the 2023 Jefferies Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
Tickers AFMD
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.